Possible scenario
RNAi Valuations Reprice
18% Chance
The acquisition is interpreted as another sign that large pharma companies are willing to pay for clinical-stage RNAi platforms after recent cardiovascular and hematology data. Silence remains the direct beneficiary, while public RNAi peers attract renewed strategic interest.
Secondary impacts
- Healthcare +0.3%
Tickers
- SLN+29.5%
- ARWR+5.6%
- ALNY+4.6%
- IONS+2.8%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.